TISIDB

Summary
Symbol	TNC
Name	tenascin C
Aliases	MGC167029; hexabrachion (tenascin); HXB; DFNA56; hexabrachion (tenascin C, cytotactin); deafness, autosomal ......
Chromosomal Location	9q33.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Secreted, extracellular space, extracellular matrix.
Domain	PF07974 EGF-like domain PF00147 Fibrinogen beta and gamma chains PF00041 Fibronectin type III domain
Function	Extracellular matrix protein implicated in guidance of migrating neurons as well as axons during development, synaptic plasticity as well as neuronal regeneration. Promotes neurite outgrowth from cortical neurons grown on a monolayer of astrocytes. Ligand for integrins alpha-8/beta-1, alpha-9/beta-1, alpha-V/beta-3 and alpha-V/beta-6. In tumors, stimulates angiogenesis by elongation, migration and sprouting of endothelial cells (PubMed:19884327).

> Gene Ontology [ TOP ]
Biological Process	GO:0001101 response to acid chemical GO:0001503 ossification GO:0001649 osteoblast differentiation GO:0001655 urogenital system development GO:0001763 morphogenesis of a branching structure GO:0003401 axis elongation GO:0007162 negative regulation of cell adhesion GO:0007528 neuromuscular junction development GO:0007584 response to nutrient GO:0009612 response to mechanical stimulus GO:0009991 response to extracellular stimulus GO:0014012 peripheral nervous system axon regeneration GO:0022612 gland morphogenesis GO:0030198 extracellular matrix organization GO:0030323 respiratory tube development GO:0030324 lung development GO:0030850 prostate gland development GO:0031099 regeneration GO:0031102 neuron projection regeneration GO:0031103 axon regeneration GO:0031667 response to nutrient levels GO:0031668 cellular response to extracellular stimulus GO:0031669 cellular response to nutrient levels GO:0031670 cellular response to nutrient GO:0032526 response to retinoic acid GO:0033273 response to vitamin GO:0033280 response to vitamin D GO:0034694 response to prostaglandin GO:0035239 tube morphogenesis GO:0042475 odontogenesis of dentin-containing tooth GO:0042476 odontogenesis GO:0043062 extracellular structure organization GO:0045471 response to ethanol GO:0048608 reproductive structure development GO:0048678 response to axon injury GO:0048732 gland development GO:0048754 branching morphogenesis of an epithelial tube GO:0050808 synapse organization GO:0060425 lung morphogenesis GO:0060441 epithelial tube branching involved in lung morphogenesis GO:0060447 bud outgrowth involved in lung branching GO:0060512 prostate gland morphogenesis GO:0060541 respiratory system development GO:0060560 developmental growth involved in morphogenesis GO:0060562 epithelial tube morphogenesis GO:0060602 branch elongation of an epithelium GO:0060638 mesenchymal-epithelial cell signaling GO:0060739 mesenchymal-epithelial cell signaling involved in prostate gland development GO:0060740 prostate gland epithelium morphogenesis GO:0061138 morphogenesis of a branching epithelium GO:0061458 reproductive system development GO:0061564 axon development GO:0071229 cellular response to acid chemical GO:0071295 cellular response to vitamin GO:0071300 cellular response to retinoic acid GO:0071305 cellular response to vitamin D GO:0071379 cellular response to prostaglandin stimulus GO:0071396 cellular response to lipid GO:0071407 cellular response to organic cyclic compound GO:0071496 cellular response to external stimulus GO:0071774 response to fibroblast growth factor GO:0071798 response to prostaglandin D GO:0071799 cellular response to prostaglandin D stimulus GO:0097305 response to alcohol
Molecular Function	GO:0045545 syndecan binding
Cellular Component	GO:0005578 proteinaceous extracellular matrix GO:0005604 basement membrane GO:0005614 interstitial matrix GO:0005924 cell-substrate adherens junction GO:0005925 focal adhesion GO:0030055 cell-substrate junction GO:0044420 extracellular matrix component

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04151 PI3K-Akt signaling pathway hsa04510 Focal adhesion hsa04512 ECM-receptor interaction
Reactome	R-HSA-3000178: ECM proteoglycans R-HSA-1474244: Extracellular matrix organization R-HSA-216083: Integrin cell surface interactions R-HSA-3000171: Non-integrin membrane-ECM interactions R-HSA-3000170: Syndecan interactions

Summary
Symbol	TNC
Name	tenascin C
Aliases	MGC167029; hexabrachion (tenascin); HXB; DFNA56; hexabrachion (tenascin C, cytotactin); deafness, autosomal ......
Chromosomal Location	9q33.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between TNC and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between TNC and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
20622113	Glioblastoma	Inhibit immunity (infiltration)	Knocking down the tenascin-C gene using the short hairpin RNA strategy converted glioma cells to a transmigration-permissive phenotype for Jurkat cells regarding ERK activation, transmigration, and amoeba-like shape formation. In addition, exogenous tenascin-C protein reduced the amoeba-like shape formation and transmigration of Jurkat cells through MCF-7 and HepG2 cell monolayers.

Summary
Symbol	TNC
Name	tenascin C
Aliases	MGC167029; hexabrachion (tenascin); HXB; DFNA56; hexabrachion (tenascin C, cytotactin); deafness, autosomal ......
Chromosomal Location	9q33.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of TNC in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	TNC
Name	tenascin C
Aliases	MGC167029; hexabrachion (tenascin); HXB; DFNA56; hexabrachion (tenascin C, cytotactin); deafness, autosomal ......
Chromosomal Location	9q33.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of TNC in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.301	0.644
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.511	0.841
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.136	0.938
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.644	0.296
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-1.153	0.695
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.013	0.998
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.98	0.202
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	1.024	0.632
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	1.005	0.662
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.378	0.817
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.202	0.585
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.494	0.0396

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of TNC in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	22.2	9.6	12.6	0.107
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	22.2	11.9	10.3	0.33
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	19	5.9	13.1	0.355
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	0	12.5	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	23.1	9.1	14	0.596
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	18.4	0	18.4	0.0356
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	13.6	0	13.6	0.279
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	25	0	25	0.103
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	9.1	0	9.1	0.458
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	20	0	20	0.294

Summary
Symbol	TNC
Name	tenascin C
Aliases	MGC167029; hexabrachion (tenascin); HXB; DFNA56; hexabrachion (tenascin C, cytotactin); deafness, autosomal ......
Chromosomal Location	9q33.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TNC. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	TNC
Name	tenascin C
Aliases	MGC167029; hexabrachion (tenascin); HXB; DFNA56; hexabrachion (tenascin C, cytotactin); deafness, autosomal ......
Chromosomal Location	9q33.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TNC. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TNC. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	TNC
Name	tenascin C
Aliases	MGC167029; hexabrachion (tenascin); HXB; DFNA56; hexabrachion (tenascin C, cytotactin); deafness, autosomal ......
Chromosomal Location	9q33.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TNC. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	TNC
Name	tenascin C
Aliases	MGC167029; hexabrachion (tenascin); HXB; DFNA56; hexabrachion (tenascin C, cytotactin); deafness, autosomal ......
Chromosomal Location	9q33.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of TNC expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	TNC
Name	tenascin C
Aliases	MGC167029; hexabrachion (tenascin); HXB; DFNA56; hexabrachion (tenascin C, cytotactin); deafness, autosomal ......
Chromosomal Location	9q33.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between TNC and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	TNC
Name	tenascin C
Aliases	MGC167029; hexabrachion (tenascin); HXB; DFNA56; hexabrachion (tenascin C, cytotactin); deafness, autosomal ......
Chromosomal Location	9q33.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting TNC collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse TNC